Stemtech Corporation (STEK)

0.0590 -0.0020 (-3.28%) At close: 03:38PM EDT

Stemtech Corporation

4851 Tamiami Trail North
Suite 200
Naples, FL 34103
United States
954 715 6000
https://www.stemtech.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Charles S. Arnold	CEO & Director	N/A	N/A	1951
Mr. John W. Meyer	President, COO & Director	120k	N/A	1955
Mr. James S. Cardwell	Chief Financial Officer	7.5k	N/A	1961
Mr. Tufan Obuz	Chief Administrative Officer	N/A	N/A	1970
Mr. Alejandro Carrillo	Vice President of Global Sales	N/A	N/A	N/A
Mr. David E. Price Esq.	Secretary	N/A	N/A	1965

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. The company offers its dietary supplements products under the RCM System, stemrelease3, Stemflo MigraStem, OraStem, and D-Fuze brand names; and skincare products under the Cellect One brand name. It serves through independent distributors. Stemtech Corporation is headquartered in Naples, Florida.

Corporate governance

Stemtech Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.